Clinical Trial Update: A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial comparing doravirine plus Truvada to efavirenz plus Truvada in HIV-1 infected participants has been completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine (doravirine)
• EFAVIRENZ (efavirenz)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2017-12-13